EMPA_(drug)

EMPA (drug)

EMPA (drug)

Chemical compound

EMPA is a selective antagonist of the OX2 receptor, with 900-fold selectivity in binding for OX2 over OX1.[1][2]

Quick Facts Clinical data, ATC code ...

See also

References

  1. [1]
    Malherbe P, Borroni E, Pinard E, Wettstein JG, Knoflach F (September 2009). "Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists". Molecular Pharmacology. 76 (3): 618–31. doi:10.1124/mol.109.055152. PMID 19542319. S2CID 5702143.
  2. [2]
    Malherbe P, Borroni E, Gobbi L, Knust H, Nettekoven M, Pinard E, et al. (April 2009). "Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor". British Journal of Pharmacology. 156 (8): 1326–41. doi:10.1111/j.1476-5381.2009.00127.x. PMC 2697736. PMID 19751316.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article EMPA_(drug), and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.